RNH1 and melanoma: However, to avoid the feedback or paradoxical activation of the MAPK pathway in NRAS mutated melanomas, the pathway was blocked at both RAF and MEK steps by using the combination of a PRi (Amgen Compd A) and a MEKi (trametinib).